Stable bone turnover markers corrected for age and gender during the first year of secukinumab treatment in radiographic axial spondyloarthritis

Clin Exp Rheumatol. 2023 Sep;41(9):1942-1943. doi: 10.55563/clinexprheumatol/i2fnno. Epub 2023 May 18.

Authors

Mark Siderius¹, Suzanne Arends², Freke Wink³, Frans G M Kroese², Anneke Spoorenberg²

Affiliations

¹ Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, the Netherlands. m.siderius@umcg.nl.
² Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, the Netherlands.
³ Rheumatology, Medical Centre Leeuwarden, the Netherlands.

PMID: 37223930
DOI: 10.55563/clinexprheumatol/i2fnno

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Bone Remodeling
Humans
Spondylarthritis* / diagnostic imaging
Spondylarthritis* / drug therapy
Spondylitis, Ankylosing* / diagnostic imaging
Spondylitis, Ankylosing* / drug therapy

Substances

secukinumab
Antibodies, Monoclonal, Humanized